First Trust Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $459K | Sell |
26,538
-172,671
| -87% | -$2.99M | ﹤0.01% | 2293 |
|
|
2025
Q1 | $4.36M | Buy |
199,209
+173,564
| +677% | +$3.8M | ﹤0.01% | 1388 |
|
|
2024
Q4 | $818K | Buy |
25,645
+8,344
| +48% | +$266K | ﹤0.01% | 2115 |
|
|
2024
Q3 | $499K | Sell |
17,301
-106,424
| -86% | -$3.07M | ﹤0.01% | 2170 |
|
|
2024
Q2 | $4.75M | Sell |
123,725
-282,758
| -70% | -$10.8M | ﹤0.01% | 1286 |
|
|
2024
Q1 | $23.9M | Buy |
406,483
+312,515
| +333% | +$18.4M | 0.02% | 729 |
|
|
2023
Q4 | $5.62M | Sell |
93,968
-304,170
| -76% | -$18.2M | 0.01% | 1198 |
|
|
2023
Q3 | $15.1M | Buy |
398,138
+320,847
| +415% | +$12.2M | 0.02% | 855 |
|
|
2023
Q2 | $7.04M | Buy |
77,291
+28,969
| +60% | +$2.64M | 0.01% | 1109 |
|
|
2023
Q1 | $3.19M | Sell |
48,322
-4,458
| -8% | -$294K | ﹤0.01% | 1465 |
|
|
2022
Q4 | $2.73M | Buy |
52,780
+27,551
| +109% | +$1.42M | ﹤0.01% | 1553 |
|
|
2022
Q3 | $1.72M | Sell |
25,229
-38,296
| -60% | -$2.62M | ﹤0.01% | 1754 |
|
|
2022
Q2 | $2.87M | Buy |
63,525
+5,716
| +10% | +$259K | ﹤0.01% | 1569 |
|
|
2022
Q1 | $2.94M | Buy |
+57,809
| New | +$2.94M | ﹤0.01% | 1612 |
|
|
2020
Q2 | – | Sell |
-57,356
| Closed | -$1.54M | – | 2359 |
|
|
2020
Q1 | $1.54M | Sell |
57,356
-12,772
| -18% | -$342K | ﹤0.01% | 1399 |
|
|
2019
Q4 | $2.15M | Buy |
70,128
+4,122
| +6% | +$126K | ﹤0.01% | 1520 |
|
|
2019
Q3 | $1.59M | Buy |
+66,006
| New | +$1.59M | ﹤0.01% | 1670 |
|